{"created":"2023-05-15T10:53:42.301725+00:00","links":{},"metadata":{"_buckets":{"deposit":"af2d4e80-07ae-4b04-b3a3-468507355be3"},"_deposit":{"id":"1364.1","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"1364.1"},"status":"published"},"_oai":{"id":"oai:miyazaki-u.repo.nii.ac.jp:00001364.1","sets":["72:30"]},"author_link":["7768","8142","8158","8139","8140","8128","8160"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2005-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"695","bibliographicPageStart":"690","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"Journal of Nephrology","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Based on observations of the clinical course of patients with IgA nephropathy （IgAN）, D'Amico et al. proposed the concept of the `point of no return （PNR）', after which progression to end-stage renal disease （ESRD） becomes inevitable. They reported that the approximate PNR is 3.0 mg/dl serum creatinine （sCr）.\nMethods: To confirm the PNR and to clarify the factors affecting the deterioration of renal function in IgAN patients, we analyzed the sequential data of those with 1.2≦ sCr <2.0 mg/dl at renal biopsy. Forty-seven patients with moderate to severe histological lesions and whose 36 month follow-up did not require renal replacement therapy, were enrolled in this study.\nResults: None of the patients who once exceeded a sCr value of 2.0 mg/dl could return to below 2.0 mg/dl during the observation period. Kaplan-Meier analysis revealed that the renal outcome of patients with average values of MBP ≧102 mmHg and/or UP score ≧2.0 until 2.0 mg/dl sCr was significantly poor. Multivariate analysis using the Cox proportional hazards model, identified only MBP and UP during the course until 2.0 mg/dl sCr as independent prognostic factors for ESRD, having hazard ratios of 2.56 （per 10mmHg; 95% CI, 1.08 to 6.05） and 4.37 （per 0.5 point; 1.36 to 14.1）, respectively.\nConclusions: We confirmed PNR as a sCr level of 2.0 mg/dl （equivalent to estimated glomerular filtration rate of 30 to 35 ml/min/1.73m2） during the course of IgAN in Japan. The management of both BP and UP until sCr has reached PNR is essential to arrest the progression to ESRD in IgAN.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wichtig Editore","subitem_publisher_language":"en"}]},"item_10001_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"16358226","subitem_relation_type_select":"PMID"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10737230","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"11218428","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小松, 弘幸","creatorNameLang":"ja"},{"creatorName":"コマツ, ヒロユキ","creatorNameLang":"ja-Kana"},{"creatorName":"Komatsu, Hiroyuki","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"藤元, 昭一","creatorNameLang":"ja"},{"creatorName":"フジモト, シヨウイチ","creatorNameLang":"ja-Kana"},{"creatorName":"Fujimoto, Shouichi","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Sato, Yuji","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hara, Seiichiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamada, Kazuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Morita, Satoshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Eto, Tanenao","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-06-21"}],"displaytype":"detail","filename":"komatsuJN200511.pdf","filesize":[{"value":"422.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"komatsuJN200511.pdf","url":"https://miyazaki-u.repo.nii.ac.jp/record/1364.1/files/komatsuJN200511.pdf"},"version_id":"b59f8ced-e68c-491c-ba55-28909b890b3d"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"End-stage renal disease, Hypertension, IgA nephropathy, Point of no return, Proteinuria","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Point of no return (PNR) in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Point of no return (PNR) in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-06-30"},"publish_date":"2009-06-30","publish_status":"0","recid":"1364.1","relation_version_is_last":true,"title":["Point of no return (PNR) in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR"],"weko_creator_id":"2","weko_shared_id":2},"updated":"2023-07-24T05:01:29.329233+00:00"}